### IMMUNO-ONCOLOGY INSIGHTS

**SEPTEMBER 2020**

**GUEST EDITOR:** Dr Jon Wigginton, former Chief Medical Officer and Senior Vice-President, Clinical Development, MacroGenics, Inc.

**Clinical development strategy**
Following the clinical success of the first wave of checkpoint inhibitors, what will move the needle again in terms of combinations in I-O?

---

**OCTOBER 2020**

**GUEST EDITOR:** Alfredo Perales-Puchalt, MD, PhD, Vice President, Research & Development, Geneos Therapeutics

**Next gen I-O approaches – what will follow the PD-1s?**
Comparing and analyzing the preclinical and clinical data generated to date for key emerging modalities to provide both pointers and address remaining obstacles to success in solid tumours

---

**NOVEMBER/DECEMBER 2020**

**GUEST EDITOR:** Ashok K. Gupta, MD, PhD, Global Clinical Head, Imfinzi Genitourinary Cancers and Tumor Agnostic Indications, AstraZeneca

**Next gen I-O approaches – what**
Addressing lingering safety issues for I-O product candidates in development

Learning more about the mechanisms of adverse reactions and how to deal with them

---

**FEBRUARY 2021**

**GUEST EDITOR:** Brent A. Hanks, MD, PhD, William Dalton Family Assistant Professor of Medical Oncology; Assistant Professor, Department of Pharmacology and Cancer Biology; Associate Director of Basic and Translational Research, Duke Center for Cancer Immunotherapy, Duke University, Duke Cancer Institute

**Understanding and overcoming mechanisms of tumour resistance**
Assessing the prospects of various methods to model and modify the tumour microenvironment

---

**APRIL 2021**

**GUEST EDITOR:** Dr Christian Schmees, Head of Tumor Biology, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Germany

**Enhancing preclinical predictivity**
What is going wrong between preclinical in vitro/in vivo and clinical in vivo settings?

---

**JUNE 2021**

**Hunting for better biomarkers of response**
Where is real progress being made in understanding why patients do and don’t respond to I-O therapeutics?

---

**JULY 2021**

**GUEST EDITOR:** Dr Christian Schmees, Head of Tumor Biology, NMI Natural and Medical Sciences Institute at the University of Tuebingen, Germany

**Enhancing preclinical predictivity**
What is going wrong between preclinical in vitro/in vivo and clinical in vivo settings?

---

**SEPTEMBER 2021**

**Leveraging cutting edge tools to convert I-O data into knowledge**
How recent advances in bioinformatics and other technological innovation are driving the future of I-O discovery and development

---

**NOVEMBER 2021**

**Bioprocessing/CMC trends, tools and techniques**
How next-gen biopharma manufacturing solutions will drive the required improvements in process and product robustness

---

**DECEMBER 2021**

**TBD**

---

Each spotlight will comprise:
- Peer-reviewed Reviews and Expert Insight articles written by leading experts in the field
- Webinars, featuring industry speakers and sponsors discussing key topics specific to the Spotlight
- Podcast, written and video interviews with key opinion leaders
- On demand roundtable discussions

**ImmuNo-Oncology Insights’ spotlights provide you with fantastic opportunities to:**
- Educate your target market about your company’s expertise, capabilities and experience
- Share your latest data with organisations looking for partners and service providers in your field
- Profile your executives and scientists as thought-leaders and KOLs
- Generate qualified leads from across the global sector
- Increase awareness of your company’s role in cell and gene therapy R&D and manufacture.